Jefferies Financial Group began coverage on shares of Aadi Bioscience (NASDAQ:AADI) in a research note released on Tuesday morning, Analyst Ratings Network reports. The brokerage issued a buy rating and a $45.00 target price on the stock.
A number of other equities research analysts have also recently issued reports on the company. Cowen started coverage on Aadi Bioscience in a research note on Friday, October 1st. They set an outperform rating on the stock. LADENBURG THALM/SH SH started coverage on Aadi Bioscience in a research note on Tuesday, September 14th. They set a buy rating and a $51.00 price objective on the stock. Zacks Investment Research cut Aadi Bioscience from a hold rating to a sell rating in a research note on Tuesday, January 4th. Finally, HC Wainwright increased their price target on Aadi Bioscience from $47.00 to $49.00 and gave the company a buy rating in a research note on Wednesday, November 24th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Buy and a consensus price target of $43.40.
Shares of Aadi Bioscience stock opened at $24.51 on Tuesday. Aadi Bioscience has a 12-month low of $14.31 and a 12-month high of $49.80. The stock has a market cap of $512.11 million, a P/E ratio of -1.83 and a beta of 1.51. The business’s 50 day moving average is $23.64 and its 200-day moving average is $26.40.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE acquired a new stake in Aadi Bioscience in the third quarter valued at about $98,000. Parallel Advisors LLC acquired a new stake in Aadi Bioscience in the third quarter valued at about $188,000. BlackRock Inc. acquired a new stake in Aadi Bioscience in the third quarter valued at about $478,000. XTX Topco Ltd acquired a new stake in Aadi Bioscience in the second quarter valued at about $29,000. Finally, Geode Capital Management LLC acquired a new stake in Aadi Bioscience in the third quarter valued at about $825,000. 64.48% of the stock is currently owned by institutional investors.
Aadi Bioscience Company Profile
Aadi Bioscience, Inc operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in October, 2011 and is headquartered in Los Angeles, CA.
Recommended Story: What does a bar chart mean for investors?
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.